It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of ...